natgillin/translations-raw huggingface dataset:
Binocrit is used: for treating symptomatic anaemia associated with kidney disease (given by injection into a vein) in children and adults on dialysis in adults on peritoneal dialysis for treating severe symptomatic anaemia caused by kidney disease in adults not yet undergoing dialysis (given by injection into a vein) for treating anaemia and reducing the need for a blood transfusion in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the doctor in moderately anaemic patients who are going to have surgery and prior to it, donate blood so that their own blood can be given to them during or after surgery (autologous predonation) as an alternative to a blood transfusion in adult patients about to undergo major orthopaedic (bone) surgery where there is a potentially high risk from blood transfusion complications
Zdravilo Binocrit se uporablja za: zdravljenje simptomatskne anemije, ki je posledica ledvične bolezni (daje se z injiciranjem v veno) pri otrocih in odraslih bolnikih, ki se zdravijo z dializo pri odraslih bolnikih, ki se zdravijo s peritonealno dializo zdravljenje hude simptomatske anemije, ki je posledica ledvične bolezni, pri odraslih bolnikih, ki se še ne zdravijo z dializo (daje se z injiciranjem v veno) zdravljenje anemije in zmanjšanje potrebe po transfuziji krvi pri odraslih bolnikih, pri katerih s kemoterapijo zdravijo solidne tumorje, maligni limfom ali multipli mielom, in imajo po oceni zdravnika večje tveganje za transfuzijo krvi zdravljenje zmerno anemičnih bolnikov, naročenih na kirurški poseg, ki pred posegom darujejo kri, da lahko med kirurškim posegom ali po njem prejmejo lastno kri (avtologna preddonacija)
BEFORE YOU USE BINOCRIT
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO BINOCRIT
Do not use Binocrit:
Ne uporabljajte zdravila Binocrit:
- if you are allergic (hypersensitive) to epoetin alfa or any of the other ingredients of Binocrit
- če ste alergični (preobčutljivi) na epoetin alfa ali katerokoli sestavino zdravila Binocrit
• you had a heart attack or stroke in the month before your treatment • you have unstable angina pectoris (new or increasing chest pain) • you are at risk of blood clots in the veins (deep venous thrombosis) – for example, if you have had clots before
• ste v mesecu pred zdravljenjem imeli srčno ali možgansko kap, • imate nestabilno angino pektoris (novo bolečino v prsnem košu ali njeno krepitev), • če pri vas obstaja nevarnost nastanka krvnih strdkov v venah (globoka venska tromboza) – na primer če ste v preteklosti imeli strdke
Take special care with Binocrit:
Bodite posebno pozorni pri uporabi zdravila Binocrit:
In all patients treated with Binocrit blood pressure should be closely monitored and treated, if necessary.
Pri vseh bolnikih, ki so zdravljeni z zdravilom Binocrit, je treba skrbno spremljati krvni tlak in ga po potrebi zdraviti.
Binocrit should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension.
Pri bolnikih z nezdravljeno, neustrezno zdravljeno ali slabo nadzorovano hipertenzijo je treba zdravilo Binocrit uporabljati previdno.
If blood pressure cannot be controlled, Binocrit treatment should be discontinued.
Če krvnega tlaka ni mogoče nadzorovati, je treba zdravljenje z zdravilom Binocrit prekiniti.
Take special care with Binocrit if you have epilepsy or chronic liver disease.
Zdravilo Binocrit je treba uporabljati še posebej previdno, če imate epilepsijo ali kronično bolezen jeter.
There may be a moderate dose-dependent increase in the platelet count within the normal range during treatment with Binocrit, which gradually regresses during the course of continued therapy.
Med zdravljenjem z zdravilom Binocrit se lahko število trombocitov, odvisno od velikosti odmerka, zmerno zveča, vendar ostane v normalnih mejah in se ob nadaljevanju zdravljenja ponovno postopoma zmanjša.
All other causes of anaemia, e. g. iron deficiency, damage of red blood cells (haemolysis), blood loss, vitamin B12 or folate deficiency, should be taken into account and treated prior to initiating therapy with Binocrit.
Pred začetkom zdravljenja z zdravilom Binocrit je treba upoštevati in zdraviti vse druge vzroke anemije, npr. pomanjkanje železa, poškodbe rdečih krvnih celic (hemoliza), izgubo krvi, pomanjkanje vitamina B12 ali folata.
In order to ensure optimum response to Binocrit adequate iron stores should be ensured.
Za optimalen odziv na zdravljenje z zdravilom Binocrit, je treba zagotoviti ustrezne zaloge železa.
Your doctor can decide whether Binocrit is not working properly for you.
Presodil bo, ali zdravilo Binocrit pri vas ne deluje ustrezno.
If you develop PRCA your Binocrit therapy will be discontinued and your doctor will decide how best to treat your anaemia.
Če se pri vas pojavi aplazija rdečih krvnih celic, bo zdravljenje z zdravilom Binocrit prekinjeno, zdravnik pa bo odločil, kako najbolje zdraviti anemijo.
There is not much experience with subcutaneous use (injection into the skin) of Binocrit in kidney patients.
S subkutano uporabo (injiciranje pod kožo) zdravila Binocrit pri ledvičnih bolnikih ni veliko izkušenj.
Therefore, if you are being treated for anaemia associated with kidney disease, Binocrit has to be given by injection into a vein (intravenously).
Če se zdravite zaradi anemije, povezane z boleznijo ledvic, je treba zdravilo Binocrit injicirati v veno (intravensko).
If an elevated or increasing serum potassium level is detected, your doctor may consider to discontinue the treatment with Binocrit until the potassium level has returned to the normal range.
Če je ugotovljeno povečanje serumske koncentracije kalija, bo zdravnik zdravljenje z zdravilom Binocrit morda prekinil, dokler se vrednosti kalija ne vrnejo v normalne meje.
An increase in dose of a particular blood-thinning medicine (heparin) during haemodialysis is frequently required during the course of therapy with Binocrit.
Med zdravljenjem z zdravilom Binocrit je treba zaradi zvečanega hematokrita med dializo pogosto zvečati odmerek posebnega zdravila za redčenje krvi (heparina).
Based on information available to date, treatment of anaemia with Binocrit in adult patients with chronic kidney failure (renal insufficiency) who do not yet require dialysis, does not accelerate the rate of progression of renal insufficiency.
Na osnovi razpoložljivih podatkov zdravljenje anemije z zdravilom Binocrit pri odraslih bolnikih s kronično ledvično odpovedjo (ledvična insuficienca), pri katerih zdravljenje z dializo še ni potrebno, ne pospešuje hitrosti napredovanja ledvične insuficience.
The 2-3 week delay between epoetin alfa administration and the appearance of desired effects should be taken into account when assessing the efficacy of Binocrit.
Pri ocenjevanju učinkovitosti zdravljenja z zdravilom Binocrit je treba upoštevati 2 - do 3- tedenski zamik med začetkom zdravljenja z epoetinom alfa in pojavom želenih učinkov.
Your doctor will check your levels of the red blood pigment (haemoglobin) regularly and adjust your dose of Binocrit accordingly to minimise the risk of blood clotting (thrombotic events).
Zdravnik bo redno preverjal vrednosti rdečega pigmenta v vaši krvi (hemoglobina) in temu ustrezno prilagodil odmerek zdravila Binocrit z namenom zmanjšanja tveganja nastanka krvnih strdkov (trombotični dogodki).
If you are a cancer patient you should be aware that Binocrit may act as a blood cell growth factor and in some circumstances may have a negative impact on your cancer.
Če ste bolnik z rakom, morate vedeti, da lahko zdravilo Binocrit deluje kot celični rastni faktor in da ima lahko v nekaterih razmerah negativen vpliv na vašo bolezen.
If you are due to have major orthopaedic surgery, the cause of anaemia should be established and treated, if possible, before the start of Binocrit treatment.
Če ste naročeni na večji ortopedski kirurški poseg, je treba ugotoviti vzrok za anemijo in jo odpraviti pred začetkom zdravljenja z zdravilom Binocrit, če je to mogoče.
Blood clots (thrombotic events) can be a risk.
Obstaja tveganje za pojav krvnih strdkov (trombotični dogodki).
190 Your doctor will weight this risk carefully against the benefits to be derived from treatment with epoetin alfa.
Zdravnik bo skrbno pretehtal to tveganje glede na koristi zdravljenja z epoetinom alfa.
If your levels of the red blood pigment (haemoglobin) are too high you should not receive Binocrit, since you have an increased risk of blood clotting after the surgery.
Če so vrednosti rdečega pigmenta v vaši krvi (hemoglobina) prevelike, zdravila Binocrit ne smete prejemati zaradi zvečanega tveganja za nastanek krvnih strdkov po operaciji.
If you are taking cyclosporin (medicine to suppress your immune system) during therapy with Binocrit, your doctor may order special blood tests to measure cyclosporin levels.
Če med zdravljenjem z zdravilom Binocrit jemljete ciklosporin (zdravilo za zaviranje imunskega sistema), lahko zdravnik naroči dodatne preiskave krvi, s katerimi bo izmeril vrednosti ciklosporina.
There is not much experience with Binocrit in pregnant women or women who are breast-feeding.
Izkušenj z zdravljenjem nosečnic in doječih mater z zdravilom Binocrit ni veliko.
Important information about some of the ingredients of Binocrit
Pomembne informacije o nekaterih sestavinah zdravila Binocrit
HOW TO USE BINOCRIT
KAKO UPORABLJATI ZDRAVILO BINOCRIT
Your doctor will conduct investigations, for example blood tests, to decide if it is necessary for you to have Binocrit.
Zdravnik bo opravil preiskave, na primer krvne preiskave, da se bo odločil, ali vas je treba zdraviti z zdravilom Binocrit.
He/ she will work out the correct dose of Binocrit for you to use and how long the treatment should continue.
Nato bo določil ustrezni odmerek zdravila Binocrit, ki ga boste uporabljali, ter kako dolgo naj bi zdravljenje potekalo.
The Binocrit pre-filled syringe is ready for use.
Z zdravilom Binocrit napolnjena injekcijska brizga je pripravljena za uporabo.
Binocrit is a sterile but unpreserved product and is for single use only.
Zdravilo Binocrit je sterilno, ne vsebuje konzervansov in je namenjeno zgolj enkratni uporabi.
Binocrit should not be shaken.
Zdravila Binocrit ne pretresajte.
At the start of your therapy, Binocrit may be injected under the supervision of experienced medical staff.
Na začetku zdravljenja se lahko zdravilo Binocrit injicira pod nadzorom izkušenega zdravniškega osebja.
Binocrit is given by injection into a vein (intravenously).
Zdravilo Binocrit se injicira v veno (intravensko).
Binocrit is given by injection under the skin (subcutaneously).
Zdravilo Binocrit se injicira pod kožo (subkutano).
When your condition has been brought under control, you will receive regular doses of Binocrit.
Ko bo stanje nadzorovano, boste dobivali redne odmerke zdravila Binocrit.
When your condition has been brought under control, you will receive regular doses of Binocrit between 25 and 50 IU/ kg twice a week in two equal injections.
Ko bo stanje nadzorovano, boste dobivali redne odmerke zdravila Binocrit, velike med 25 in 50 i. e. / kg, dvakrat na teden, v dveh enakih odmerkih.
After your condition has been brought under control, you will receive regular doses of Binocrit between 17 and 33 IU/ kg, three times a week.
Ko bo nadzor dosežen, boste dobivali redne odmerke zdravila Binocrit, med 17 in 33 i. e. na kilogram, trikrat na teden.
Alternatively, Binocrit can be administered as an initial dose of 450 IU/ kg once a week by injection under the skin.
Zdravilo Binocrit je mogoče dajati tudi enkrat na teden, pri čemer je začetni odmerek 450 i. e. / kg, ki se injicira pod kožo.
Treatment with Binocrit should be continued until one month after the end of chemotherapy.
Zdravljenje z zdravilom Binocrit je treba nadaljevati še en mesec po končanem zdravljenju s kemoterapijo.
You will receive Binocrit during the 3 weeks before your surgery.
Med
You will also take iron supplements before and during Binocrit treatment to increase the effectiveness of Binocrit.
202 zdravljenjem z zdravilom Binocrit in po njem boste jemali tudi nadomestno železo za povečanje učinka zdravila Binocrit.
It is important that levels of iron in your blood are normal throughout Binocrit treatment.
Pomembno je, da so med zdravljenjem z zdravilom Binocrit vrednosti železa v vaši krvi normalne.
Where appropriate you will receive oral doses of iron, ideally starting before the Binocrit treatment begins.
Če je potrebno, boste prejeli peroralne odmerke železa, ki jih je treba začeti jemati pred zdravljenjem z zdravilom Binocrit.
If you are a kidney patient Binocrit has to be given by injection into a vein.
Če ste ledvični bolnik, je treba zdravilo Binocrit injicirati v veno.
At the start of your therapy, Binocrit may be injected by medical staff.
Na začetku zdravljenja vam bo zdravilo Binocrit injiciralo medicinsko osebje.
However, your doctor may decide that it is right for you to learn how to inject Binocrit under the skin yourself.
Toda zdravnik se lahko odloči, da je za vas primerno, da se zdravilo Binocrit naučite pod kožo injicirati sami.
Inject the Binocrit solution.
Injicirajte raztopino zdravila Binocrit.
If you inject more Binocrit than you should
Če ste uporabili večji odmerek zdravila Binocrit, kot bi smeli
You should inform the doctor immediately if you think too much Binocrit has been injected.
Če mislite, da ste uporabili prevelik odmerek zdravila Binocrit, o tem takoj obvestite svojega zdravnika.
Like all medicines, Binocrit can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Binocrit neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
PRCA means the inability to produce enough red blood cells in the bone (see section “ Take special care with Binocrit”).
Aplazija rdečih krvnih celic pomeni nezmožnost nastajanja zadostnega števila rdečih krvnih celic v kosteh (glejte poglavje » Bodite posebno pozorni pri uporabi zdravila Binocrit «).
Your doctor may monitor your blood pressure regularly while you are using Binocrit, particularly at the start of therapy.
Zdravnik lahko med zdravljenjem z zdravilom Binocrit redno spremlja vaš krvni tlak, še posebej na začetku zdravljenja.
- blood clotting (thrombotic vascular events) (see section “ Take special care with Binocrit”).
- Krvni strdki (trombotični žilni dogodki) (glejte poglavje » Bodite posebno pozorni pri uporabi
- increase of blood pressure.
zdravila Binocrit «).
with underlying cardiovascular disease: after donating blood repeatedly vascular and thrombotic events (blood clotting) can occur independently of treatment with Binocrit.
z obstoječo boleznijo srca in ožilja: ne glede na zdravljenje z zdravilom Binocrit se lahko po darovanju krvi večkrat pojavijo žilni in trombotični dogodki (strjevanje krvi).
Treatment with Binocrit may be associated with an increased risk of blood clotting after the surgery (postoperative thrombotic/ vascular disorders) if your levels of the red blood pigment are too high.
Če so vrednosti rdečega pigmenta v krvi prevelike, je zdravljenje z zdravilom Binocrit lahko povezano z zvečanim tveganjem za pojav krvnih strdkov po operativnem posegu (pooperativne trombotične žilne motnje).
HOW TO STORE BINOCRIT
SHRANJEVANJE ZDRAVILA BINOCRIT
- Do not use this medicine after the expiry date which is stated on the label and carton after
- Zdravila Binocrit ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na
- You may take Binocrit out of the refrigerator and keep it at room temperature (up to 25°C) for
- Zdravilo Binocrit lahko vzamete iz hladilnika in ga hranite pri sobni temperaturi (ne višji od
What Binocrit contains
Kaj vsebuje zdravilo Binocrit
Binocrit 1000 IU/ 0.5 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.5 ml solution for injection contains 1000 international units (IU) corresponding to 8.4 micrograms epoetin alfa Binocrit 2000 IU/ 1 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 1 ml solution for injection contains 2000 international units (IU) corresponding to 16.8 micrograms epoetin alfa Binocrit 3000 IU/ 0.3 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.3 ml solution for injection contains 3000 international units (IU) corresponding to 25.2 micrograms epoetin alfa Binocrit 4000 IU/ 0.4 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.4 ml solution for injection contains 4000 international units (IU) corresponding to 33.6 micrograms epoetin alfa Binocrit 5000 IU/ 0.5 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.5 ml solution for injection contains 5000 international units (IU) corresponding to 42.0 micrograms epoetin alfa Binocrit 6000 IU/ 0.6 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.6 ml solution for injection contains 6000 international units (IU) corresponding to 50.4 micrograms epoetin alfa Binocrit 7000 IU/ 0.7 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.7 ml solution for injection contains 7000 international units (IU) corresponding to 58.8 micrograms epoetin alfa Binocrit 8000 IU/ 0.8 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.8 ml solution for injection contains 8000 international units (IU) corresponding to 67.2 micrograms epoetin alfa Binocrit 9000 IU/ 0.9 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.9 ml solution for injection contains 9000 international units (IU) corresponding to 75.6 micrograms epoetin alfa Binocrit 10 000 IU/ 1 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 1 ml solution for injection contains 10 000 international units (IU) corresponding to 84.0 micrograms epoetin alfa
Binocrit 10. 000 i. e. / 1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi: ena napolnjena
195 What Binocrit looks like and contents of the pack
Izgled zdravila Binocrit in vsebina pakiranja
Binocrit 1000 IU/ 0.5 ml solution for injection in a pre-filled syringe The syringes contain 0.5 ml (1000 IU) of solution.
Brizga vsebuje 0, 5 ml (1. 000 i. e.) raztopine.
Binocrit 2000 IU/ 1 ml solution for injection in a pre-filled syringe The syringes contain 1 ml (2000 IU) of solution.
Brizga vsebuje 1 ml (2. 000 i. e.) raztopine.
Binocrit 3000 IU/ 0.3 ml solution for injection in a pre-filled syringe The syringes contain 0.3 ml (3000 IU) of solution.
Brizga vsebuje 0, 3 ml (3. 000 i. e.) raztopine.
Binocrit 4000 IU/ 0.4 ml solution for injection in a pre-filled syringe The syringes contain 0.4 ml (4000 IU) of solution.
Brizga vsebuje 0, 4 ml (4. 000 i. e.) raztopine.
Binocrit 5000 IU/ 0.5 ml solution for injection in a pre-filled syringe The syringes contain 0.5 ml (5000 IU) of solution.
Brizga vsebuje 0, 5 ml (5. 000 i. e.) raztopine.
Binocrit 6000 IU/ 0.6 ml solution for injection in a pre-filled syringe The syringes contain 0.6 ml (6000 IU) of solution.
Brizga vsebuje 0, 6 ml (6. 000 i. e.) raztopine.
Binocrit 7000 IU/ 0.7 ml solution for injection in a pre-filled syringe The syringes contain 0.7 ml (7000 IU) of solution.
Brizga vsebuje 0, 7 ml (7. 000 i. e.) raztopine.
Binocrit 8000 IU/ 0.8 ml solution for injection in a pre-filled syringe The syringes contain 0.8 ml (8000 IU) of solution.
Brizga vsebuje 0, 8 ml (8. 000 i. e.) raztopine.
Binocrit 9000 IU/ 0.9 ml solution for injection in a pre-filled syringe The syringes contain 0.9 ml (9000 IU) of solution.
Brizga vsebuje 0, 9 ml (9. 000 i. e.) raztopine.
Binocrit 10 000 IU/ 1 ml solution for injection in a pre-filled syringe The syringes contain 1 ml (10 000 IU) of solution.
Brizga vsebuje 1 ml (10. 000 i. e.) raztopine.
Hexal AG Industriestraße 25 D-83607 Holzkirchen Germany
Hexal AG Industriestraße 25 D- 83607 Holzkirchen Nemčija
6 Младост 4, 1766-София Тел.: +359 2 970 47 47
6 Младост 4, 1766- София Тел.: +359 2 970 47 47 Česká republika Sandoz s. r. o.
Malta Sandoz GmbH Biochemiestr.
20 H- 1034 Budapest Tel.: +36 1 430 2890 Malta Sandoz GmbH Biochemiestr.
France Sandoz SAS Direction Scientifique et Marketing Biotech 49, avenue Georges Pompidou F-92593 Levallois-Perret Cedex
207 France Sandoz SAS Direction Scientifique et Marketing Biotech 49, avenue Georges Pompidou F- 92593 Levallois- Perret Cedex Tél: +33 1 49 64 48 00
Biograstim is a ‘ biosimilar’ medicine.
Zdravilo Biograstim je podobno biološko zdravilo.
This means that Biograstim is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘ reference medicine’).
„ referenčno zdravilo “).
Biograstim is used to stimulate the production of white blood cells in the following situations: • to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing); • to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia; • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections; • to treat persistent neutropenia in patients with advanced human immunodeficiency virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Zdravilo Biograstim se uporablja za spodbujanje tvorbe belih krvničk v naslednjih primerih: • za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in zmanjšanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo kemoterapijo (zdravljenje proti raku), ki je citotoksična (ubija celice); • za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (kot npr. pri bolnikih z levkemijo), pri katerih obstaja tveganje za dlje trajajočo hudo nevtropenijo; • za povečanje števila nevtrofilcev in zmanjšanje tveganja za okužbe pri bolnikih z nevtropenijo, ki so imeli v preteklosti hujše, ponavljajoče se okužbe; • za zdravljenje netropenije pri bolnikih z napredovalo okužbo z virusom humane imunske pomanjkljivosti (HIV), z namenom zmanjšanja tveganja za bakterijske okužbe, ko druge oblike zdravljenja niso primerne.
How it is given, the dose and the duration of treatment depend on why it is being used, the patient’ s body weight and the response to treatment.
Način dajanja, odmerek in trajanje zdravljenja so odvisni od namena uporabe, telesne mase bolnika in odziva na zdravljenje.
The active substance in Biograstim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Učinkovina v zdravilu Biograstim, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G- CSF).
Filgrastim is produced by a method known as ‘ recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Filgrastim se izdeluje z metodo, imenovano „ tehnologija rekombinantne DNK “: proizvaja ga bakterija, ki je prejela gen (DNK), s pomočjo katerega postane sposobna tvoriti filgrastim.
To study the safety of Biograstim, two further studies were carried out in patients with lung cancer and with non-Hodgkin’ s lymphoma.
Za preučitev varnosti zdravila Biograstim sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
During the first 21-day chemotherapy cycle, patients treated with either Biograstim or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo.
Med prvim 21 dnevnim ciklom kemoterapije so imeli bolniki, zdravljeni bodisi z zdravilom Biograstim ali Neupogen, hudo netropenijo v povprečju 1, 1 dan, v primerjavi s 3, 8 dnevi pri tistih, ki so prejemali placebo.